Literature DB >> 26433589

Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant.

Paul E Gray1,2, Tracey A O'Brien2,3, Mayura Wagle4,5, Stuart G Tangye4,5, Umaimainthan Palendira4,5, Tony Roscioli6,7, Sharon Choo8, Rosemary Sutton9, John B Ziegler1,2, Katie Frith10,11.   

Abstract

UNLABELLED: Vasculitis occurs rarely in association with X-linked lymphoproliferative disease (XLP). There are four published cases of non-EBV XLP-associated cerebral vasculitis reported, none of whom have survived without major cognitive impairment. CASE: A 9-year old boy initially presented aged 5 years with a restrictive joint disease. He subsequently developed dysgammaglobulinemia, episodic severe pneumonitis, aplastic anaemia, gastritis and cerebral vasculitis. A diagnosis of XLP was made, based on flow cytometric analysis and the identification of a novel mutation in SH2D1A, c.96G>C. No peripheral blood lymphocyte clonal proliferation was identified and he was EBV negative, although human herpes virus-7 (HHV7) was detected repeatedly in his cerebrospinal fluid. He underwent a reduced intensity unrelated umbilical cord blood transplant, but failed to engraft. A second 5/6 matched cord gave 100 % donor engraftment. Complications included BK virus-associated haemorrhagic cystitis, a possible NK-cell mediated immune reconstitution syndrome and post-transplant anti-glomerular basement membrane disease, the latter treated with cyclophosphamide and rituximab. At +450 days post-transplant he is in remission from his vasculitis and anti-glomerular basement membrane disease, and HHV-7 has remained undetectable.
CONCLUSION: This is the second published description of joint disease in XLP, and only the fourth case of non-EBV associated cerebral vasculitis in XLP, as well as being the first to be successfully treated for this manifestation. This case raises specific questions about vasculitis in XLP, in particular the potential relevance of HHV-7 to the pathogenesis.

Entities:  

Keywords:  HHV-7; X-linked lymphoproliferative disease (XLP); haematopoietic stem cell transplant; vasculitis

Mesh:

Substances:

Year:  2015        PMID: 26433589     DOI: 10.1007/s10875-015-0194-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  18 in total

1.  X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.

Authors:  Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients.

Authors:  L Yin; V Ferrand; M F Lavoué; D Hayoz; N Philippe; G Souillet; M Seri; R Giacchino; E Castagnola; S Hodgson; B S Sylla; G Romeo
Journal:  Hum Genet       Date:  1999-11       Impact factor: 4.132

3.  Control of human herpes virus type 8-associated diseases by NK cells.

Authors:  Maria C Sirianni; Massimo Campagna; Donato Scaramuzzi; Maurizio Carbonari; Elena Toschi; Ilaria Bacigalupo; Paolo Monini; Barbara Ensoli
Journal:  Ann N Y Acad Sci       Date:  2007-01       Impact factor: 5.691

Review 4.  The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990.

Authors:  D T Purtilo; H L Grierson; J R Davis; M Okano
Journal:  Pediatr Pathol       Date:  1991 Sep-Oct

5.  Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients.

Authors:  M Morra; M Simarro-Grande; M Martin; A S Chen; A Lanyi; O Silander; S Calpe; J Davis; T Pawson; M J Eck; J Sumegi; P Engel; S C Li; C Terhorst
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

6.  [An analysis of etiological and genetic factors of a patient with familial hemophagocytic lymphohistiocytosis].

Authors:  Hong-Xing Liu; Chun-Rong Tong; Hui Wang; Juan Zhu; Fang Wang; Peng Cai; Wen Teng; Jun-Fang Yang; Ya-Li Zhang; Dao-Pei Lu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2011-02

7.  Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency).

Authors:  Jana Pachlopnik Schmid; Danielle Canioni; Despina Moshous; Fabien Touzot; Nizar Mahlaoui; Fabian Hauck; Hirokazu Kanegane; Eduardo Lopez-Granados; Ester Mejstrikova; Isabelle Pellier; Lionel Galicier; Claire Galambrun; Vincent Barlogis; Pierre Bordigoni; Alain Fourmaintraux; Mohamed Hamidou; Alain Dabadie; Françoise Le Deist; Filomeen Haerynck; Marie Ouachée-Chardin; Pierre Rohrlich; Jean-Louis Stephan; Christelle Lenoir; Stéphanie Rigaud; Nathalie Lambert; Michèle Milili; Claudin Schiff; Helen Chapel; Capucine Picard; Geneviève de Saint Basile; Stéphane Blanche; Alain Fischer; Sylvain Latour
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

8.  X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis.

Authors:  Hirokazu Kanegane; Yoshikiyo Ito; Koichi Ohshima; Takeshi Shichijo; Kunio Tomimasu; Keiko Nomura; Takeshi Futatani; Ryo Sumazaki; Toshio Miyawaki
Journal:  Am J Hematol       Date:  2005-02       Impact factor: 10.047

Review 9.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

Review 10.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

View more
  8 in total

1.  Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8-deficient patients.

Authors:  Bethany A Pillay; Danielle T Avery; Joanne M Smart; Theresa Cole; Sharon Choo; Damien Chan; Paul E Gray; Katie Frith; Richard Mitchell; Tri Giang Phan; Melanie Wong; Dianne E Campbell; Peter Hsu; John B Ziegler; Jane Peake; Frank Alvaro; Capucine Picard; Jacinta Bustamante; Benedicte Neven; Andrew J Cant; Gulbu Uzel; Peter D Arkwright; Jean-Laurent Casanova; Helen C Su; Alexandra F Freeman; Nirali Shah; Dennis D Hickstein; Stuart G Tangye; Cindy S Ma
Journal:  JCI Insight       Date:  2019-04-25

2.  Late-Onset Non-HLH Presentations of Growth Arrest, Inflammatory Arachnoiditis, and Severe Infectious Mononucleosis, in Siblings with Hypomorphic Defects in UNC13D.

Authors:  Paul Edgar Gray; Bella Shadur; Susan Russell; Richard Mitchell; Michael Buckley; Kerri Gallagher; Ian Andrews; Kevin Thia; Joseph A Trapani; Edwin Philip Kirk; Ilia Voskoboinik
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

Review 3.  Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.

Authors:  Sylvain Latour; Sarah Winter
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

4.  Case Report: Meningoencephalitis With Thrombotic Occlusive Vasculopathy in a Young EBV-Naïve Boy Is Associated With a Novel SH2D1A Mutation.

Authors:  Jolanda Steininger; Raphael Rossmanith; Christoph B Geier; Alexander Leiss-Piller; Lukas Thonhauser; Simone Weiss; Johannes A Hainfellner; Michael Freilinger; Wolfgang M Schmidt; Martha M Eibl; Hermann M Wolf
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

Review 5.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

6.  Potential pathogenic mechanism of type 1 X-linked lymphoproliferative syndrome caused by a mutation of SH2D1A gene in an infant: A case report.

Authors:  Yanchun Wang; Yan Wang; Weimin Lu; Lvyan Tao; Yang Xiao; Yuantao Zhou; Xiaoli He; Yu Zhang; Li Li
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

7.  Development and Validation of a Targeted Next-Generation Sequencing Gene Panel for Children With Neuroinflammation.

Authors:  Dara McCreary; Ebun Omoyinmi; Ying Hong; Ciara Mulhern; Charalampia Papadopoulou; Marina Casimir; Yael Hacohen; Rodney Nyanhete; Helena Ahlfors; Thomas Cullup; Ming Lim; Kimberly Gilmour; Kshitij Mankad; Evangeline Wassmer; Stefan Berg; Cheryl Hemingway; Paul Brogan; Despina Eleftheriou
Journal:  JAMA Netw Open       Date:  2019-10-02

8.  Molecular Analysis of Goodpasture's Disease Following Hematopoietic Stem Cell Transplant in a Pediatric Patient, Recalls the Conformeropathy of Wild-Type Anti-GBM Disease.

Authors:  Paul E Gray; Hugh McCarthy; Owen M Siggs; Moin A Saleem; Tracy O' Brien; Katie Frith; John B Ziegler; A Richard Kitching; Agnes B Fogo; Billy G Hudson; Vadim Pedchenko
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.